BRIM Biotechnology Enters Trading in Taiwan
BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases.
BRIM has several novel drug products in its pipeline using the company’s proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform.
BRIM’s lead candidate BRM421 has the potential to be a first-in-class peptide treatment for dry eye syndrome (DES). Phase 2/3 clinical trials completed in the US demonstrate that the drug has the potential to speed up the repair of corneal damage through stimulation of corneal stem cell proliferation and differentiation, as well as to treat disease symptoms, according to a company news release. Data demonstrate that BRM421 is safe and well-tolerated with a unique early onset curative effect.1
“Our goal is restoration and repair of the damage caused by DES. The PDSP technology platform underpinning BRM421 and other assets in our pipeline could revolutionize the ophthalmology and degenerative joint disease fields," Chairwoman and CEO Dr. Haishan Jang said in a company news release. "If successful, BRM421 could treat millions of people around the world living with DES and provide an excellent example of a first-in-class new drug developed in Asia. OTC trading brings us one step closer to achieving our vision to bring sustainable and affordable healthcare innovation to the world.”
“With this next step of OTC trading, we are excited to progress development at an accelerated pace and will continue our journey in ophthalmology to bring the first regenerative peptide therapy for DES to the market in the near future, as well as apply our learnings to a wide range of other diseases with significantly unmet needs,” said Dr. Jang.